Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials

被引:35
作者
Dicembrini, Ilaria [1 ,2 ]
Nreu, Besmir [1 ,2 ]
Montereggi, Chiara [1 ,2 ]
Mannucci, Edoardo [1 ,2 ]
Monami, Matteo [1 ,2 ]
机构
[1] Careggi Hosp, Diabetol, Via Oblate 4, I-50141 Florence, Italy
[2] Univ Florence, Via Oblate 4, I-50141 Florence, Italy
关键词
DPP-4; inhibitors; Meta-analysis; Cancer; POOLED ANALYSIS; SAFETY; SITAGLIPTIN; PANCREATITIS; TOLERABILITY; SAXAGLIPTIN; METFORMIN; THERAPY;
D O I
10.1007/s00592-020-01479-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Observational studies and meta-analyses of randomized trials on dipeptidyl peptidase-4 inhibitors (DPP4i) reported discordant results on the risk of malignancies with this class of drugs. Aim of the present meta-analysis is the assessment of the effect of DPP4i treatment on the incidence of different types of cancer, collecting all available evidence from randomized controlled trials. Methods An extensive MEDLINE, EMBASE, and Cochrane database search for sitagliptin or vildagliptin or omarigliptin or saxagliptin or alogliptin or trelagliptin or anagliptin or linagliptin or gemigliptin or evogliptin or teneligliptin was performed up to September 30th, 2019. All trials performed on type 2 diabetes, with duration >= 24 weeks, and comparing of DPP4i with placebo or active drugs were collected. The study has been registered on PROSPERO (#153344). Mantel-Haenszel odds ratio (MH-OR) with 95% confidence interval (95% CI) was calculated for all outcomes. Results A total of 157 eligible trials were identified. DPP-4i were not associated with an increased risk of overall cancer (MH-OR 0.93 [0.86, 1.00]; p = 0.07), with no significant differences across individual molecules of the class. When compared with placebo/none, a lower risk of cancer with DPP-4i was observed in placebo-controlled trials (MH-OR 0.90 [0.82, 0.99], p = 0.030), whereas no significant differences have been detected with any other comparators. DPP-4i was associated with a significant reduction in colorectal cancer (MH-OR 0.70 [0.53, 0.94], p = 0.020). Conclusions Available data do not support the hypothesis of an association of DPP4i treatment with malignancies, with a possible beneficial effect for colon-rectal cancer.
引用
收藏
页码:689 / 696
页数:8
相关论文
共 30 条
  • [1] Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
    Abrahami, Devin
    Douros, Antonios
    Yin, Hui
    Yu, Oriana H. Y.
    Faillie, Jean-Luc
    Montastruc, Francois
    Platt, Robert W.
    Bouganim, Nathaniel
    Azoulay, Laurent
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [2] Evaluation of Anti Cancer Effects of Dpp-4 Inhibitors in Colon Cancer- An Invitro Study
    Amritha, C. A.
    Kumaravelu, Punnagai
    Chellathai, D. Darling
    [J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2015, 9 (12) : FC14 - FC16
  • [3] Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin
    Capuano, Annalisa
    Sportiello, Liberata
    Maiorino, Maria Ida
    Rossi, Francesco
    Giugliano, Dario
    Esposito, Katherine
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 989 - 1001
  • [4] Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
    Elashoff, Michael
    Matveyenko, Aleksey V.
    Gier, Belinda
    Elashoff, Robert
    Butler, Peter C.
    [J]. GASTROENTEROLOGY, 2011, 141 (01) : 150 - 156
  • [5] Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
    Engel, Samuel S.
    Round, Elizabeth
    Golm, Gregory T.
    Kaufman, Keith D.
    Goldstein, Barry J.
    [J]. DIABETES THERAPY, 2013, 4 (01) : 119 - 145
  • [6] Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study
    Faillie, Jean-Luc
    Azoulay, Laurent
    Patenaude, Valerie
    Hillaire-Buys, Dominique
    Suissa, Samy
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
  • [7] Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats
    Femia, Angelo Pietro
    Raimondi, Laura
    Maglieri, Giulia
    Lodovici, Maura
    Mannucci, Edoardo
    Caderni, Giovanna
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (10) : 2498 - 2503
  • [8] Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink
    Hicks, Blanaid M.
    Yin, Hui
    Yu, Oriana H. Y.
    Pollak, Michael N.
    Platt, Robert W.
    Azoulay, Laurent
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2016, 355
  • [9] Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus
    Hirshberg, Boaz
    Parker, Artist
    Edelberg, Helen
    Donovan, Mark
    Iqbal, Nayyar
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (07) : 556 - 569
  • [10] Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors
    Htoo, Phyo T.
    Buse, John B.
    Gokhale, Mugdha
    Marquis, M. Alison
    Pate, Virginia
    Sturmer, Til
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (08) : 1013 - 1023